Aptamer-SH2 superbinder-based targeted therapy for pancreatic ductal adenocarcinoma.
An-Dong LiuJie ZhouXiao-Yang BiGuo-Qing HouShawn Shun-Cheng LiQing ChenHui XuXuan CaoPublished in: Clinical and translational medicine (2022)
XQ-2d-SH2 CM-(Arg)9 conjugate may efficiently destroy the pancreatic stroma and show potent antitumor efficacy with minimal toxic effect by regulating tumor cell proliferation and metastasis in vitro and in vivo, which makes it to be a promising targeted therapy of PDAC.